"Hidden Gem" Yahoo Finance 1y Target Est: 15.38
151.88M Market Cap, 69.50M Cash, 4.33M Debt
% Institutional Holdings 53.48
AND TOO alliances with Stanford University
Home Page
kosan.com
Clinical Trials
kosan.com
Currently Kosan Biosciences is conducting Clinical Trials in the following
indications:
• Solid tumors
• Multiple Myeloma
• Chronic Myeloid Leukemia
• Breast Cancer
• Prostate Cancer
Intellectual Property
kosan.com
As of December 31, 2003, Kosan owns or has exclusive licenses to 80 U.S. patents, 130 pending U.S. patent applications, 22 foreign patents, and 90 foreign patent applications. Some of the issued U.S. patents owned or exclusively licensed to Kosan include:
Kosan Biosciences Inc (KOSN) - Key Statistics
finance.yahoo.com
VALUATION MEASURES
Market Cap (intraday): 151.88M
Price/Sales (ttm): 5.08
Price/Book (mrq): 1.98
FINANCIAL HIGHLIGHTS
Total Cash (mrq): 69.50M
Total Cash Per Share (mrq): 2.39
Total Debt (mrq)²: 4.33M
Total Debt/Equity (mrq): 0.057
Current Ratio (mrq): 4.811
Book Value Per Share (mrq): 2.617
Share Statistics
Average Volume (3 month): 73,863
Average Volume (10 day): 136,000
Shares Outstanding: 29.10M
Float: 22.10M
% Held by Insiders: 24.05%
% Held by Institutions: 53.48%
Kosan uses its proprietary technologies to develop drug candidates from an important class of natural product compounds known as polyketides. Polyketides are a rich source of many pharmaceuticals, including antibiotics (e.g., Zithromax, Biaxin, erythromycin and tetracyclines), anticancer drugs (e.g., doxorubicin), cholesterol-lowering drugs (e.g., Zocor, Mevacor and Pravachol), immunosuppressants (e.g., FK506 and rapamycin) and other therapeutics. However, polyketides are made in very small amounts in microorganisms and are difficult to make or modify chemically.
Kosan's technologies enable the generation of novel polyketides as potential new drugs and the cost-effective production of novel and existing polyketides. These technologies include genetic manipulation of polyketide-producing organisms to introduce specific alterations in the structure of known polyketides, chemical derivatization, and production of polyketides through heterologous production in recombinant organisms, total chemical synthesis or a combination of the two.
Kosan's strategy is to apply its technologies to create new polyketides for pharmaceutical development, to make improved versions of known polyketide pharmaceuticals and to advance selected drug candidates into clinical trials. We are co-developing epothilones for the treatment of cancer with Roche and have U.S. co-marketing rights for epothilones approved for marketing. Our lead anti-cancer product candidate, KOS-862 (Epothilone D) is in Phase II human trials. In collaboration with the NCI, we are developing geldanamycin analogs for the treatment of cancer. The lead product, 17-AAG, is in Phase Ia human trials. Kosan has ketolide antibiotic product candidates in preclinical evaluation and two additional programs with product candidates in preclinical studies: discodermolide analogs for the treatment of cancer and non-antibiotic erythromycin derivatives for the treatment of gastro-intestinal motility disorders.
Voluntary Disclosure Voluntary Disclosure Voluntary Disclosure Voluntary Disclosure Voluntary Disclosure Voluntary Disclosure Voluntary Disclosure Voluntary Disclosure Voluntary Disclosure
KOSN - KOSAN BIOSCIENCES INC
Buy 3,000 Market Day Only 2:54 pm 03/07/2005
Bought 100 5.23 2:54 pm 03/07/2005
Bought 100 5.24 2:54 pm 03/07/2005
Bought 100 5.23 2:54 pm 03/07/2005
Bought 200 5.24 2:54 pm 03/07/2005
Bought 100 5.24 2:54 pm 03/07/2005
Bought 2,400 5.266 2:54 pm 03/07/2005
Status: CLOSED - Filled
Buy 2,000 Market Day Only 3:12 pm 03/07/2005
Bought 2000 5.24 3:13 pm 03/07/2005
Status: CLOSED - Filled |
